摘要
目的:分析了解富马酸喹硫平治疗女性精神分裂症的疗效和安全性.方法:将40例女性精神分裂症患者分为治疗组和对照各20例.治疗组患者给予富马酸喹硫平,起始量为50毫克/日,最大剂量为600毫克/日,平均剂量(342.3±62.4)毫克/日,分2次口服.对照组患者给予氯氮平,平均剂量为(384. 2 ±76.8)毫克,每日分2次口服.两组均单一用药,疗程6～12周.比较两组临床疗效、症状评分和不良反应.结果:治疗组有效率为75%,对照组有效率为70%.两组有效率比较疗效相当.两组治疗前后症状评分比较,表1有极显著性(P<0.01),治疗组不良反应发生率低于对照组.结论:富马酸喹硫平治疗女性精神分裂症的疗效与氯氮平相近,其不良反应少,依从性好,安全性高.
Objective: To analyse the efficacy and security of Quetiapine to the female schizophrene. Methods: 40 female schizophrene were assigned into 2 medication groups. Therapy group was taken Quetiapine, from 50mg/d to 600mg/d, which average dosage was 342.3±62.4mg/d, twice. Contrast group was taken Clozapine which average dosage was 384.2±76.8mg/d, twice. The period of treatment is from six to twelve weeks. Then compare the efficacy and side effects of two groups. Results: Efficacious ratio of the therapy group is 75%, the contrast group is 70%. There isn't significant difference in efficacious ratio. The chart 1 shows significant difference after treatment. Side effects of therapy group was less than contrast group. Conclusions: Quetiapine is close to Clozapine in the efficacy to female schizophrene. Qutiapine has less side effects, good compliance and better security.
出处
《中国民康医学》
2005年第6期269-270,共2页
Medical Journal of Chinese People’s Health
